Arbutus Biopharma ABUS Cash Flow Statement (2010-2026)

NASDAQ ABUS
$5.14 +0.02 (+0.29%)
As of: Sep 4, 2026 · 3:12 PM EDT
Reported Financials

Arbutus Biopharma Quarterly Cash Flow Statement

Periods 57 quarters
Latest Jun 2026

Arbutus Biopharma reported cash from operations of -$6.02M and free cash flow of -$6.02M for the quarter ended Jun 2026, up 61.8% year over year. This cash flow statement covers 57 quarters of results from Dec 2010 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Dec2010 Dec2011 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-19.16M-21.32M-15.77M-14.19M-17.57M-21.93M-16.34M-17.09M-20.10M-19.31M-17.86M-19.79M-19.72M-12.50M-24.53M2.50M-7.73M-4.43M169.71M-5.14M
Share-based CompensationStock Comp.
1.61M1.43M1.74M2.06M1.72M1.67M2.13M2.96M2.48M1.72M2.01M3.18M2.16M1.63M3.56M0.86M1.26M1.26M1.36M1.62M
Deferred Taxes
Gains from Investment SecuritiesGains Investment
0.86M0.19M0.20M0.21M0.21M1.61M0.27M-0.64M0.20M0.23M0.18M0.21M0.34M1.89M0.30M0.26M0.27M-2.66M0.21M0.21M
Asset Writedowns and ImpairmentWritedown
Cash from Restructuring
Cash from OperationsCash from Ops.
-16.04M-19.61M20.62M-20.29M-18.69M-16.99M-27.30M-19.56M-21.78M-17.29M-19.30M-14.50M-20.74M-10.31M-13.39M-15.75M-5.82M-4.68M-8.11M-6.02M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
-0.30M-0.25M-0.17M-0.08M0.08M0.22M0.39M0.53M0.66M0.62M0.55M0.68M0.98M0.92M0.72M0.67M0.54M0.42M0.35M0.32M
Depreciation & Amortization (CF)Dep. & Amort.
0.45M0.39M0.38M0.34M0.33M0.34M0.37M0.35M0.36M0.34M0.33M0.01M0.01M0.01M0.01M
Change in Working Capital
Change in ReceivablesChange Receivables
0.37M-0.77M0.41M0.66M-0.14M-0.48M1.31M-0.05M-0.44M-0.40M0.36M-0.37M-0.16M0.80M-1.23M-0.16M-0.12M0.13M178.74M0.63M
Change in Accured ExpensesChange Accured Exp.
1.17M1.33M-2.10M3.76M-0.20M3.76M-6.38M-0.85M1.00M0.47M-2.02M2.86M-3.56M0.02M4.54M-7.60M0.14M0.81M-0.98M-1.62M
Change in TaxesChange Taxes
Other Working Capital ChangesOther WC Changes
Investing Activities
Capital ExpendituresCapex
0.02M0.06M0.07M0.21M0.09M0.13M0.12M0.86M0.03M0.10M0.00M0.09M
Sales of Property, Plant and EquipmentPP&E (Sale)
-0.02M0.02M0.35M
Acquisitions
Change in Acquisitions & DivestmentsChange Acquisitions
16.00M20.00M2.00M9.00M19.00M26.00M37.00M31.50M17.53M46.24M37.19M42.41M28.35M56.69M46.06M44.10M41.28M23.83M16.00M22.00M
Cash from Investing ActivitiesCash from Investing
15.97M-8.12M-60.06M-13.83M-13.74M12.68M16.68M1.44M10.43M22.23M11.69M9.83M-11.99M13.41M11.35M15.61M-10.02M-1.36M2.20M-1.66M
Financing Activities
Other financing activitiesOther financing
1.98M-0.12M0.24M0.16M0.30M0.28M-0.05M2.45M2.01M1.59M1.42M2.65M0.45M0.79M1.64M11.53M3.15M
Cash from Financing ActivitiesCash from Financing
46.95M59.12M11.48M0.11M9.13M11.08M20.42M4.74M1.68M3.81M24.43M24.37M1.77M1.42M2.78M0.45M0.84M1.64M11.62M3.15M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
44.74M59.24M0.30M0.30M9.00M11.30M19.90M4.70M1.40M3.90M21.80M22.40M
Additional items
Exchange Rate EffectFX Effect
0.04M0.01M-0.02M-0.00M0.00M-0.00M0.01M0.01M-0.01M-0.01M0.01M-0.03M0.00M0.02M-0.01M0.00M-0.01M-0.00M
Change in Cash
46.93M31.40M-27.95M-34.01M-23.32M6.77M9.80M-13.38M-9.67M8.75M16.82M19.69M-30.94M4.48M0.75M0.34M-15.00M-4.40M5.70M-4.54M
Free Cash FlowFCF
-16.06M-19.66M20.54M-20.50M-18.78M-17.12M-27.42M-20.42M-21.82M-17.29M-19.39M-14.51M-20.74M-10.40M-13.39M-15.75M-5.82M-4.68M-8.11M-6.02M
Net Cash FlowNCF
46.88M31.39M-27.95M-34.01M-23.30M6.78M9.79M-13.38M-9.67M8.74M16.83M19.70M-30.95M4.52M0.74M0.32M-14.99M-4.40M5.71M-4.53M